$15.90▼-0.18 (-1.12%)
Pre-Market:$15.85-0.05 (-0.31%)
Ultragenyx Pharmaceutical Inc. (RARE)
Stock-Based Compensation
$135.29M
TTM · Period ending: · USD

RARE Stock-Based Compensation
Latest reported$135.29Mperiod ending
Latest reported$135.29Mperiod ending
RARE Stock-Based Comp ($254.00K → $135.29M)
Annual stock-based compensation
High-resolution chart · PNG
What is stock-based compensation?
Non-cash compensation expense paid in equity.
RARE stock-based compensation history
Annual fiscal periods · USD. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | Stock-Based Compensation (USD) |
|---|---|
| 153,000,000 | |
| 158,030,000 | |
| 135,213,000 | |
| 130,377,000 | |
| 104,952,000 | |
| 85,735,000 | |
| 81,995,000 | |
| 80,107,000 | |
| 68,014,000 | |
| 48,309,000 | |
| 24,884,000 | |
| 5,394,000 | |
| 657,000 | |
| 891,000 | |
| 254,000 |
Explore More
RARE Financial Metrics
Explore 130+ historical metrics & ratios
Stock Comparison
Compare equities side by side
52-Week Highs Breakout
Stocks breaking to new annual highs
52-Week Lows Oversold
S&P 500 oversold value screener
Trending Momentum
Relative strength momentum leaders
Earnings Calendar
Upcoming earnings dates & reports
S&P 500 Screener
Filter and sort all 500 stocks
Market Movers
Today's biggest gainers and losers
Market Heatmap
Visual sector performance